SWM
MDGL icon

Spire Wealth Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Spire Wealth Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed -$45.9K – 2422
2025
Q3 		$45.9K Sell
100
-150
-60% -$56K ﹤0.01% 1270
2025
Q2 		$75.7K Buy
250
+150
+150% +$44.7K ﹤0.01% 1076
2025
Q1 		$33.1K Hold
100
– – ﹤0.01% 1433
2024
Q4 		$30.9K Hold
100
– – ﹤0.01% 1465
2024
Q3 		$21.2K Hold
100
– – ﹤0.01% 1424
2024
Q2 		$28K Buy
+100
New +$23.8K ﹤0.01% 1312

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Spire Wealth Management's MDGL Position: Q4 2025 in Review

Spire Wealth Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 100 shares — an estimated $45.9K sold.

Spire Wealth Management first reported a position in MDGL in Q2 2024 and held it in 6 quarters. The position peaked at $75.7K in Q2 2025. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • Spire Wealth Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Spire Wealth Management sold 100 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $45.9K.
  • Spire Wealth Management first reported a position in Madrigal Pharmaceuticals in Q2 2024 and held it in 6 quarters.
  • Spire Wealth Management's Madrigal Pharmaceuticals position peaked at $75.7K in Q2 2025.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Spire Wealth Management's 13F filing for Q4 2025, filed 14 Jan 2026.